Spyre Therapeutics, Inc. (SYRE)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 18
in 88 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Spyre Therapeutics’ loss widened sharply in the third fiscal quarter of 2026, and EPS of -$0.94 trailed the -$0.79 estimate by -$0.15, based on preliminary results reported November 3, 2026. Net income was a loss of about $96.1 million, down -759.5% year over year from a loss of about $11.2 million a year ago, alongside an operating loss of roughly $105.7 million. EPS also deteriorated -526.7% year over year from -$0.15. Cash use remained elevated, with negative operating cash flow of about $77.5 million. Consensus for the next period calls for EPS of -$0.87.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a preclinical Biotechnology company listed on the NASDAQ Capital Market as SYRE that develops treatments for inflammatory bowel disease. The company focuses on drug candidates for people with ulcerative colitis and Crohn's disease, placing it in the biotech side of the healthcare sector.
Today's Snapshot
SYRE closed 4.2% below yesterday's close, while its sector was flat.
Trading Volume
Below 10d avg (973.1K)
770.4K
vs S&P 500 Today
Underperforming Market
-0.67%
Updated: November 20, 2026 at 21:11 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$74.85 - $98.79Sell
- RSI (14)46.18Neutral
- Stochastic %K (14, 3, 3)26.58Neutral
- MACD Level (12, 26)1.70Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.